MX2020005565A - Proceso para la preparacion de compuestos enlazantes de farmaco. - Google Patents

Proceso para la preparacion de compuestos enlazantes de farmaco.

Info

Publication number
MX2020005565A
MX2020005565A MX2020005565A MX2020005565A MX2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A
Authority
MX
Mexico
Prior art keywords
drug linker
preparation
linker compounds
compounds
paboh
Prior art date
Application number
MX2020005565A
Other languages
English (en)
Inventor
Sophie Blanchard
James Coats
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2020005565A publication Critical patent/MX2020005565A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción se relaciona de manera general con procesos novedosos para la preparación de compuestos enlazantes de fármaco y composiciones que comprenden esos compuestos enlazantes de fármaco.
MX2020005565A 2017-11-30 2018-11-29 Proceso para la preparacion de compuestos enlazantes de farmaco. MX2020005565A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593104P 2017-11-30 2017-11-30
PCT/US2018/063070 WO2019108797A1 (en) 2017-11-30 2018-11-29 Process for the preparation of drug linker compounds

Publications (1)

Publication Number Publication Date
MX2020005565A true MX2020005565A (es) 2020-08-20

Family

ID=66665808

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005565A MX2020005565A (es) 2017-11-30 2018-11-29 Proceso para la preparacion de compuestos enlazantes de farmaco.
MX2023009372A MX2023009372A (es) 2017-11-30 2020-07-13 Proceso para la preparacion de compuestos enlazantes de farmaco.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009372A MX2023009372A (es) 2017-11-30 2020-07-13 Proceso para la preparacion de compuestos enlazantes de farmaco.

Country Status (15)

Country Link
US (2) US11612666B2 (es)
EP (1) EP3717016A4 (es)
JP (2) JP7402159B2 (es)
KR (1) KR20200094185A (es)
CN (1) CN111417408B (es)
AU (1) AU2018375412A1 (es)
BR (1) BR112020010503A2 (es)
CA (1) CA3082165A1 (es)
EA (1) EA202091340A1 (es)
IL (1) IL274757A (es)
MA (1) MA51870A (es)
MX (2) MX2020005565A (es)
SG (1) SG11202004698RA (es)
WO (1) WO2019108797A1 (es)
ZA (1) ZA202003037B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717575B2 (en) 2019-05-20 2023-08-08 Mabplex International Co., Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
CN110945009B (zh) * 2019-10-23 2023-10-31 烟台迈百瑞国际生物医药股份有限公司 一种寡肽连接子中间体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2007031734A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
CA2662981A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
CN110078787A (zh) * 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
LT3418281T (lt) * 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
US9533483B2 (en) 2014-09-26 2017-01-03 Kimberly-Clark Worldwide, Inc. Apparatus for and method of shaping and applying a segment to a moving web

Also Published As

Publication number Publication date
CN111417408B (zh) 2024-04-23
US20200360532A1 (en) 2020-11-19
EA202091340A1 (ru) 2020-10-16
JP2023164652A (ja) 2023-11-10
MA51870A (fr) 2020-10-07
SG11202004698RA (en) 2020-06-29
US20240042052A1 (en) 2024-02-08
CA3082165A1 (en) 2019-06-06
EP3717016A1 (en) 2020-10-07
ZA202003037B (en) 2023-12-20
CN111417408A (zh) 2020-07-14
US11612666B2 (en) 2023-03-28
KR20200094185A (ko) 2020-08-06
JP7402159B2 (ja) 2023-12-20
WO2019108797A1 (en) 2019-06-06
IL274757A (en) 2020-07-30
JP2021505542A (ja) 2021-02-18
EP3717016A4 (en) 2021-09-01
MX2023009372A (es) 2023-08-16
AU2018375412A1 (en) 2020-05-28
BR112020010503A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12017502203A1 (en) Tyrosine kinase inhibitors
GEP20207056B (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
NZ702752A (en) Methods for synthesizing amatoxin building block and amatoxins
MX2022015106A (es) Proceso para preparar tapinarof.
WO2015121379A3 (en) Process for producing vanillin
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
PH12018500852A1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
WO2019224790A3 (en) Prodrugs of fulvestrant
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2023009372A (es) Proceso para la preparacion de compuestos enlazantes de farmaco.
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
PH12019500198A1 (en) Compounds and compositions and uses thereof
IN2015CH01182A (es)
MD4793C1 (ro) Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MY184366A (en) Pyrazines modulators of gpr6
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2021004996A (es) Preparacion de 4-metiltetrahidropiranos 2-sustituidos a partir de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos como materiales de partida.
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin